The closest match is AER-011, a well-characterized antibody targeting the extracellular domain of EphA1, a receptor tyrosine kinase involved in cell signaling and cancer progression .
Target: EphA1 (UniProt P21709)
Epitope: Amino acids 457–471 (C-terminus of extracellular domain)
Species Reactivity: Human, rat, mouse
Applications:
Western blot
Live-cell imaging
Flow cytometry
Application | Sample Type | Result |
---|---|---|
Western blot | Human Jurkat cells | Clear band at ~110 kDa |
Immunocytochemistry | Mouse brain membranes | Specific membrane staining |
AB011 is a humanized IgG1 antibody targeting Claudin18.2 (CLDN18.2), a tight junction protein overexpressed in gastric and pancreatic cancers .
In acquired angioedema (AAE), autoantibodies against C1-inhibitor (C1-INH) drive pathogenic effects. While not named "AAE11," these antibodies are critical diagnostic markers :
Marker | Sensitivity | Specificity |
---|---|---|
IgM-AntiC1INH complex | 85% | 96% |
IgG-AntiC1INH complex | 65% | 88% |
Question: How can I validate the specificity of the AAE11 antibody in my experimental design?
Answer: Validation of antibody specificity is crucial for reliable research outcomes. You can use orthogonal methods such as Western blot, immunohistochemistry (IHC), and ELISA to confirm the antibody's target specificity. Additionally, comparing results from multiple antibodies targeting the same antigen can enhance validation .
Question: What strategies can I employ to resolve contradictory data when using the AAE11 antibody across different experimental conditions?
Answer: Contradictory data may arise from variations in experimental conditions or antibody batch differences. To resolve this, ensure consistent experimental conditions, use controls, and validate results with multiple batches of the antibody. Also, consider using computational models to predict potential binding modes and specificity profiles .
Question: How can I assess the cross-reactivity of the AAE11 antibody with closely related antigens, and what implications does this have for my research?
Answer: Assessing cross-reactivity involves testing the antibody against a panel of related antigens using techniques like ELISA or Western blot. This is crucial for understanding potential off-target effects and ensuring specificity in complex biological systems. Utilize biophysics-informed models to predict and design antibodies with customized specificity profiles .
Question: What criteria should I use to select an appropriate antibody for my research, considering factors like citations and user reviews?
Answer: When selecting an antibody, consider its citation history in peer-reviewed publications, as this indicates independent validation. Tools like CiteAb can help identify well-cited antibodies. Additionally, user reviews can provide valuable insights into practical performance, though they may be less reliable than peer-reviewed data .
Question: How can I ensure reproducibility in my research when using the AAE11 antibody, given the challenges associated with antibody characterization?
Answer: To enhance reproducibility, thoroughly characterize the antibody using multiple validation methods. Ensure consistent experimental conditions and consider using multiple antibodies to confirm findings. Regularly update your methods based on emerging best practices and recommendations from the scientific community .
Question: What advanced techniques can I use to design or optimize antibodies like AAE11 for improved specificity and affinity?
Answer: Techniques such as phage display and biophysics-informed modeling can be used to design antibodies with customized specificity profiles. These methods allow for the prediction and generation of novel antibody sequences with enhanced affinity and specificity for target antigens .
Question: How can I interpret the results of experiments using the AAE11 antibody in complex biological systems where cross-reactivity might occur?
Answer: Interpretation requires careful consideration of potential cross-reactivity and off-target effects. Use controls and validate findings with orthogonal methods. Consider using computational models to predict potential interactions and design follow-up experiments to confirm specificity .
Question: What future directions in antibody research might improve the utility and reliability of antibodies like AAE11?
Answer: Future directions include the development of more specific and cross-reactive antibodies using advanced biotechnological methods. Additionally, integrating computational models with experimental approaches will enhance antibody design and validation, leading to more reliable research outcomes .